CClinicalTrials.gg
CompletedNCT05841979LEMURS-PUpdated Apr 17, 2025

The Lived Experiences Measured Using Rings Pilot Study

A Phase 2 interventional study of Moodlifters and Physical Activity in Depression, Stress and Sleep, sponsored by University of Vermont. Completed at 1 site in United States. Open to participants aged 18 Years to 25 Years. Per ClinicalTrials.gov, last updated 2025-04-17.

Sponsored by University of Vermont · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2022, registered Apr 2023).
Phase
Phase 2
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Study summary

The transition to college is a period of elevated risk for a range of mental health conditions. For students with pre-existing mental health diagnoses, the added pressures can exacerbate challenges. Although colleges and universities strive to provide mental health support to their students, the high demand for these services makes it difficult to provide scalable cost-effective solutions. To address these issues, the present study aims to compare the efficacy of three different treatments using a large cohort of 600 students transitioning to college. Interventions were selected based on their potential for generalizability and cost-effectiveness on college campuses. The randomized controlled trial will assign 150 participants to one of four arms: 1) group-based therapy, 2) physical activity program, 3) nature experiences group, or 4) self-monitoring condition as the control group. In addition, biometric data will be collected from all participants using a wearable device to develop algorithmic predictions of mental and physical health functioning. Once recruitment is complete, modeling strategies will be used to evaluate the outcomes and effectiveness of each intervention. The findings of this study will provide evidence as to the benefits of implementing scalable and proactive interventions using technology with the goal of improving well-being and success of new college students.

02

Conditions studied

  • Depression
  • Stress
  • Sleep
  • Anxiety

Browse trials for

03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's enrollment of 188 is above the median of 84 across 6,720 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

University of Vermont is the lead sponsor of 215 studies on the registry; 28 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Current undergraduate student in their first year of school
  • own a mobile device

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    group-based therapy

    Group therapy delivered via moodlifters

    Behavioral: Moodlifters

  • Experimental
    physical activity

    Physical Activity and Exercise

    Behavioral: Physical Activity

  • Experimental
    nature experience

    Nature Experiences

    Behavioral: Nature Experiences

  • No intervention
    self-monitoring

    Placebo control

Interventions

  • BehavioralMoodlifters

    Mood Lifters, a novel mental wellness program, was developed as a more accessible means to provide psychotherapy (Votta \& Deldin, 2022). Meetings covered biopsychosocial areas and skills that were drawn from multiple therapeutic interventions consistent with a biopsychosocial framework. Areas included physical health, negative thoughts, problem-solving, emotional awareness and regulation, building relationships, behavioral activation, and using a strengths-based approach. ML is delivered by peer leaders who are individuals that have completed the program as well as a training program.

  • BehavioralPhysical Activity

    Participants randomized to the exercise arm received 14 weeks of a structured weekly strength and conditioning training program to enhance muscle mass, strength, cardiorespiratory fitness, and overall well-being. The program is based on previous research showing that cardiorespiratory fitness and muscle strength/size can both contribute to decreased mortality/increased longevity and enhanced mental health (Burke et al., 2017; McLeod et al., 2016; Srikanthan \& Karlamangla, 2014; Strasser \& Burtscher, 2018). The training program consists of three training sessions per week, with one being an in-person group session guided by a certified strength and conditioning specialist. The other two training sessions are self-guided via the mobile app Trainheroic. This weekly training schedule aligns with previous research showing benefits to structuring an exercise program using a variety of social contexts (group setting, own, etc.; Burke et al., 2017).

  • BehavioralNature Experiences

    Participants randomized to the Nature Experiences participated in 14 weeks of group and self-directed activities to connect with the natural environment. Weekly group activities will be led by Nature Guides, who are undergraduate and graduate students with extensive outdoor education training. Group activities will last one hour a week and include hiking in forests, walking in parks, bird-watching, mindfulness exercises, and snow activities. Participants will be given a list of self-directed activity suggestions each week. The goal of self-directed activities is to spend an additional two hours in a natural environment each week.

06

What researchers measure

Primary outcomes

  1. Depression as measured by Depression, Anxiety, Stress Survey - 21 (Depression subscale)

    Self Reported Depression

    Time frame: Change in depression scores from time of randomization through 5 months

  2. Anxiety as measured by Depression, Anxiety, Stress Survey - 21 (Anxiety subscale)

    Self ReportedAnxiety

    Time frame: Change in anxiety scores from time of randomization through 5 months

  3. Stress as measured by Depression, Anxiety, Stress Survey - 21 (Stress subscale)

    Self Reported Stress

    Time frame: Change in stress scores from time of randomization through 5 months

  4. Well-Being as measured by Warwick-Edinburgh Mental Well-being Scale

    Self Reported well-being

    Time frame: Change in well-being scores from time of randomization through 5 months

  5. Stress as measured by the Perceived Stress Scale

    Self Reported subclinical stress

    Time frame: Change in stress scores from time of randomization through 5 months

Secondary outcomes

  1. Sleep Quality Index

    Self Reported Sleep

    Time frame: Change in sleep quality scores from time of randomization through 5 months

  2. Oura Ring Sleep Index

    Biometric Sleep recorded from an Oura Ring

    Time frame: Change in Oura Sleep measured scores from time of randomization through 5 months

  3. Medical Outcomes Social Support Survey

    Social Support

    Time frame: Change in social support scores scores from time of randomization through 5 months

07

Study locations

1 site
  • University of Vermont
    Burlington, Vermont 05405, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05841979
Lead sponsor
University of Vermont
Collaborators
MassMutual - Private Industry Funded
Responsible party
Matthew Price (Professor, University of Vermont) — Principal investigator
First posted
May 3, 2023
Start date
Dec 1, 2022
Primary completion
Jun 1, 2024
Completion
Jun 1, 2024
Last update
Apr 17, 2025

Study contacts

Laura Bloomfield, MD, PhD
principal investigator · University of Vermont
Chris Danforth, PhD
principal investigator · University of Vermont
Ryan McGinnis, PhD
principal investigator · University of Vermont
Ellen McGinnis, PhD
principal investigator · University of Vermont
Matthew Price, PhD
principal investigator · University of Vermont

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion